PREDICTIVE AND PROGNOSTIC ANGIOGENIC MARKERS IN A GYNECOLOGIC ONCOLOGY GROUP PHASE II TRIAL OF BEVACIZUMAB IN RECURRENT AND PERSISTENT OVARIAN OR PERITONEAL CANCER

OBJECTIVE: Potential predictive/prognostic angiogenic markers were prospectively examined in a phase II trial of bevacizumab in epithelial ovarian cancer (EOC)/primary peritoneal cancer (PPC). METHODS: Recurrent/persistent EOC/PPC patients were treated with bevacizumab (15mg/kg IV q21days) until dis...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Han, Ernest S., Burger, Robert A., Darcy, Kathleen M., Sill, Michael W., Randall, Leslie M., Chase, Dana, Parmakhtiar, Basmina, Monk, Bradley J., Greer, Benjamin E., DeGeest, Koen, Fruehauf, John P.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2975758/
https://ncbi.nlm.nih.gov/pubmed/20870280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2010.08.016
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares